BJH - volume 9, issue Abstract Book BSTH, february 2018
K.R. Six , W. Delabie , R. Devloo , L. Johnson , D.C. Marks , L. Dumont , K.M. Devreese , H.B. Feys PhD, Prof V. Compernolle PhD
BJH - volume 8, issue 5, september 2017
B. Van Aelst PhD, J. Coene MD, H.B. Feys PhD, M.P. Emonds MD, PhD, K. Van Poucke MD, J. Moerman MD, E. Verhoye , Prof V. Compernolle PhD
We report three cases of massive ex vivo coagulation in a leukocyte depleted red cell concentrate during transfusion. Molecular blood typing indicated that patient blood was present in the filter housing of the infusion set and/or in the blood bag itself. Together with the history of events, this suggested that the observed clotting was caused by backflow of patient blood. Therefore, we recommend maintaining the blood bag above heart level during the entire transfusion procedure, until the infusion set is removed.
(BELG J HEMATOL 2017;8(5):195–7)
Read moreBJH - volume 7, issue 6, december 2016
B. Van Aelst PhD, H.B. Feys PhD, R. Devloo , Prof P. Vandekerckhove PhD, Prof V. Compernolle PhD
Pathogen inactivation technologies are photochemical treatments developed to decrease transfusion transmitted infections. However, the impact of pathogen inactivation technologies on the blood components themselves is not entirely clear. Therefore, we investigated the quality of blood components following pathogen inactivation. First, the impact of three different pathogen inactivation technologies on plasma was compared. The different methods all negatively affected ADAMTS13 activity and antigen level, but to different degrees. The pathogen inactivation technology using riboflavin as a photosensitizer had the largest effect. This effect was caused by reactive oxygen because removal of dissolved molecular oxygen prevented protein damage to occur. Next, we investigated the influence of three different pathogen inactivation technologies on platelet concentrates. For this, platelet function was assessed in microfluidic flow chamber experiments. These indicated a decreased platelet function compared to untreated controls for all pathogen inactivation technologies. Additional experiments showed that the underlying mechanisms of platelet damage were different for every pathogen inactivation technology, but all three resulted in similar thrombus formation deficiencies in flow chambers. We focused on one particular pathogen inactivation technology which combines the photosensitizer amotosalen (a psoralen) and UVA light (PUVA). The data showed a specific inhibition of the phosphatidylinositol 3-kinase signal transduction pathway caused by covalent binding of amotosalen to phospholipids during photoactivation. As the combination of a psoralen with UVA light is clinically used off-label for graft-versus-host disease treatment, phosphatidylinositol 3-kinase signal transduction in T lymphocytes of patient samples was studied and also here inhibition of phosphatidylinositol 3-kinase signal transduction was found. To conclude, research that initiated from the observation that platelet and plasma function is decreased following pathogen inactivation technologies has revealed an overall effect of PUVA on cellular phosphatidylinositol 3-kinase signal transduction by covalent modification of phospholipids.
(BELG J HEMATOL 2016;7(6):240–3)
Read moreBJH - 2014, issue Abstract Book BSTH, november 2014
B. Van Aelst PhD, H.B. Feys PhD, R. Devloo , Prof P. Vandekerckhove PhD, J. Coene MD, Prof V. Compernolle PhD
BJH - 2014, issue Abstract Book BSTH, november 2014
B. Van Aelst PhD, R. Devloo , Prof P. Vandekerckhove PhD, Prof V. Compernolle PhD, H.B. Feys PhD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
